Regadenoson (CV Therapeutics/Astellas). CV Therapeutics and Astellas (formerly Fujisawa) are codeveloping the adenosine A2A receptor agonist regadenoson as a potential adjunctive intravenous pharmacological imaging agent in cardiac perfusion studies for the potential detection of coronary artery disease. Positive results from the first of two phase III clinical studies were reported in August 2005.